The purpose of this study was to investigate the hydrolyzation of aspirin during the process of dissolution testing for aspirin delayed-release tablets. Hydrolysis product of salicylic acid can result in adverse effec...The purpose of this study was to investigate the hydrolyzation of aspirin during the process of dissolution testing for aspirin delayed-release tablets. Hydrolysis product of salicylic acid can result in adverse effects and affect the determination of dissolution rate assaying. In this study, the technique of differential spectra was employed, which made it possible to monitor the dissolution testing in situ. The results showed that the hydrolyzation of aspirin made the percentage of salicylic acid exceed the limit of free salicylic acid (4.0), and the hydrolyzation may affect the quality detection of aspirin delayed-release tablets.展开更多
目的:考察不同厂家生产的阿司匹林肠溶片体外实时释放曲线,比较不同来源阿司匹林肠溶片释放行为的差异,为提高阿司匹林肠溶片的处方设计和质量控制提供思路及手段。方法:采用光纤药物释放度实时测定仪,测定各厂家阿司匹林肠溶片在p H 6...目的:考察不同厂家生产的阿司匹林肠溶片体外实时释放曲线,比较不同来源阿司匹林肠溶片释放行为的差异,为提高阿司匹林肠溶片的处方设计和质量控制提供思路及手段。方法:采用光纤药物释放度实时测定仪,测定各厂家阿司匹林肠溶片在p H 6.8(中国药典2010年版)、p H 6.8(日本橙皮书)、p H 6.0(日本橙皮书)、p H 4.0缓冲液和p H 1.2盐酸溶液5种释放介质中的实时释放曲线。结果:参比制剂在2种p H 6.8和p H 6.0缓冲液释放介质中,50 min内的释放量均可达到80%;以p H 6.8缓冲液(中国药典2010年版)为释放介质,31家企业的阿司匹林肠溶片在45 min内的释放量均大于80%,且均一性良好;以p H 6.0缓冲液(日本橙皮书)为释放介质,部分企业的阿司匹林肠溶片在50 min内的释放量均小于20%,且180 min内的释放量仍小于50%;以p H 6.8缓冲液(日本橙皮书)为释放介质,仅有部分厂家的阿司匹林肠溶片在2种p H 6.8缓冲液中表现出相似的释放行为,另一部分厂家的阿司匹林肠溶片释放较慢或不释放;p H 4.0缓冲液和p H1.2盐酸溶液为溶出介质,参比制剂和受试制剂均未释放。结论:参比制剂在p H 6.0以及不同离子种类及强度下的p H 6.8的缓冲液释放介质中均能释放,表明参比制剂在大部分肠道内均能够进行释放,并且受肠道内环境影响较小。部分企业阿司匹林肠溶片与参比制剂在释放度行为上存在差异,需重视处方工艺的进一步研究;建议采用多条释放曲线评价阿司匹林肠溶片的质量。展开更多
基金supported by the Xinjiang Medical University Scientific Innovation Fund (No. XJC201129)Xinjiang Uygur Autonomous Region Natural Science Fund (No. 2011211A041)
文摘The purpose of this study was to investigate the hydrolyzation of aspirin during the process of dissolution testing for aspirin delayed-release tablets. Hydrolysis product of salicylic acid can result in adverse effects and affect the determination of dissolution rate assaying. In this study, the technique of differential spectra was employed, which made it possible to monitor the dissolution testing in situ. The results showed that the hydrolyzation of aspirin made the percentage of salicylic acid exceed the limit of free salicylic acid (4.0), and the hydrolyzation may affect the quality detection of aspirin delayed-release tablets.
文摘目的:考察不同厂家生产的阿司匹林肠溶片体外实时释放曲线,比较不同来源阿司匹林肠溶片释放行为的差异,为提高阿司匹林肠溶片的处方设计和质量控制提供思路及手段。方法:采用光纤药物释放度实时测定仪,测定各厂家阿司匹林肠溶片在p H 6.8(中国药典2010年版)、p H 6.8(日本橙皮书)、p H 6.0(日本橙皮书)、p H 4.0缓冲液和p H 1.2盐酸溶液5种释放介质中的实时释放曲线。结果:参比制剂在2种p H 6.8和p H 6.0缓冲液释放介质中,50 min内的释放量均可达到80%;以p H 6.8缓冲液(中国药典2010年版)为释放介质,31家企业的阿司匹林肠溶片在45 min内的释放量均大于80%,且均一性良好;以p H 6.0缓冲液(日本橙皮书)为释放介质,部分企业的阿司匹林肠溶片在50 min内的释放量均小于20%,且180 min内的释放量仍小于50%;以p H 6.8缓冲液(日本橙皮书)为释放介质,仅有部分厂家的阿司匹林肠溶片在2种p H 6.8缓冲液中表现出相似的释放行为,另一部分厂家的阿司匹林肠溶片释放较慢或不释放;p H 4.0缓冲液和p H1.2盐酸溶液为溶出介质,参比制剂和受试制剂均未释放。结论:参比制剂在p H 6.0以及不同离子种类及强度下的p H 6.8的缓冲液释放介质中均能释放,表明参比制剂在大部分肠道内均能够进行释放,并且受肠道内环境影响较小。部分企业阿司匹林肠溶片与参比制剂在释放度行为上存在差异,需重视处方工艺的进一步研究;建议采用多条释放曲线评价阿司匹林肠溶片的质量。